Biophysical properties of the clinical-stage antibody landscape
暂无分享,去创建一个
K Dane Wittrup | Yingda Xu | Michael Brown | Isabelle Caffry | Heather Lynaugh | Tingwan Sun | Yao Yu | Tushar Jain | Stéphanie Durand | Amy Hall | Nga Rewa Houston | Juergen H Nett | Beth Sharkey | Beata Bobrowicz | Yuan Cao | Hemanta Baruah | Laura T Gray | Eric M Krauland | Maximiliano Vásquez | T. Jain | K. Wittrup | E. Krauland | J. Nett | Yingda Xu | Tingwan Sun | M. Vásquez | Beata Bobrowicz | Heather Lynaugh | Isabelle Caffry | Yao Yu | Yuan Cao | Michael E Brown | H. Baruah | Laura T. Gray | L. Gray | Stéphanie Durand | A. Hall | N. R. Houston | Beth Sharkey | Michael E. Brown | Hemanta Baruah | Nga Rewa Houston
[1] H. Kettenberger,et al. Developability assessment during the selection of novel therapeutic antibodies. , 2015, Journal of pharmaceutical sciences.
[2] Feng Wang,et al. Somatic hypermutation maintains antibody thermodynamic stability during affinity maturation , 2013, Proceedings of the National Academy of Sciences.
[3] Ken A. Dill,et al. In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability , 2014, Proceedings of the National Academy of Sciences.
[4] Steffen Hartmann,et al. Best Practices in Assessment of Developability of Biopharmaceutical Candidates , 2015 .
[5] T. W. Anderson,et al. Asymptotic Theory of Certain "Goodness of Fit" Criteria Based on Stochastic Processes , 1952 .
[6] Peter M Tessier,et al. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. , 2013, Molecular pharmaceutics.
[7] K D Wittrup,et al. Protein Folding Stability Can Determine the Efficiency of Escape from Endoplasmic Reticulum Quality Control* , 1998, The Journal of Biological Chemistry.
[8] R. M. Owen,et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.
[9] Lisa J. Bernstein,et al. A strategy for risk mitigation of antibodies with fast clearance , 2012, mAbs.
[10] S. Jacobs,et al. Cross-Interaction Chromatography: A Rapid Method to Identify Highly Soluble Monoclonal Antibody Candidates , 2009, Pharmaceutical Research.
[11] K Dane Wittrup,et al. Target-independent variable region mediated effects on antibody clearance can be FcRn independent , 2016, mAbs.
[12] Ying Tang,et al. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies , 2015, mAbs.
[13] Linda O Narhi,et al. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. , 2011, Journal of pharmaceutical sciences.
[14] Thomas Emrich,et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics , 2014, Proceedings of the National Academy of Sciences.
[15] K D Wittrup,et al. Secretion efficiency in Saccharomyces cerevisiae of bovine pancreatic trypsin inhibitor mutants lacking disulfide bonds is correlated with thermodynamic stability. , 1998, Biochemistry.
[16] Deborah S. Goldberg,et al. Plasmonic measurements of monoclonal antibody self‐association using self‐interaction nanoparticle spectroscopy , 2014, Biotechnology and bioengineering.
[17] Melissa L Geddie,et al. A novel screening method to assess developability of antibody-like molecules , 2015, mAbs.
[18] Yingda Xu,et al. High throughput detection of antibody self-interaction by bio-layer interferometry , 2013, mAbs.
[19] Maxim N. Artyomov,et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.
[20] N. Warne,et al. Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[21] Yingda Xu,et al. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies , 2015, mAbs.
[22] Abner Louis Notkins,et al. Half-life of polyreactive antibodies , 1994, Journal of Clinical Immunology.
[23] K Dane Wittrup,et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. , 2013, Protein engineering, design & selection : PEDS.
[24] Kiichi Fukui,et al. Fc domain mediated self-association of an IgG1 monoclonal antibody under a low ionic strength condition. , 2011, Journal of bioscience and bioengineering.
[25] Mohammed Shameem,et al. Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions. , 2014, Journal of pharmaceutical sciences.
[26] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[27] K Dane Wittrup,et al. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice , 2015, mAbs.
[28] Stacey Spencer,et al. Solubility evaluation of murine hybridoma antibodies , 2012, mAbs.
[29] Olga Obrezanova,et al. Aggregation risk prediction for antibodies and its application to biotherapeutic development , 2015, mAbs.
[30] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[31] William F Weiss,et al. High-throughput analysis of concentration-dependent antibody self-association. , 2011, Biophysical journal.
[32] Bernhardt L Trout,et al. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. , 2012, Journal of pharmaceutical sciences.
[33] Yingda Xu,et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy , 2014, mAbs.